TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06942572: A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Starg

Sponsor: Splice Bio · Phase: PHASE1/PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 57 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$14,008,000

Rescue Site Savings

+$9,236,525

Unlock Full NCT06942572 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06942572 Rescue Dossier →